TPG Capital aims to sell its clinical trials business Novotech by the end of this year, preparing the formal sales documents for distribution later this month.
The private equity firm has set its sights on rival investment firms as probable buyers of the business, which could fetch TPG at least $3 billion, three people familiar with the process told The Australian Financial Review.
Loading...
Aaron Weinman is a correspondent at The Australian Financial Review who covers investment banks, private equity firms and the broader capital markets. Connect with Aaron on Twitter. Email Aaron at aaron.weinman@afr.com
Anthony Macdonald is a Chanticleer columnist. He is a former Street Talk co-editor and has 10 years' experience as a business journalist and worked at PwC, auditing and advising financial services companies. Connect with Anthony on Twitter. Email Anthony at a.macdonald@afr.com
